Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
On Thursday, Mizuho (NYSE:MFG) Securities reiterated its Outperform rating on Autolus Therapeutics plc (NASDAQ:AUTL), with a steady price target of $12.00, significantly above the current trading price of $1.75. According to InvestingPro data, analyst targets range from $7.60 to $14.00, suggesting substantial upside potential. The endorsement follows Autolus’ recent fourth-quarter earnings call, which highlighted the ongoing launch of its therapy Aucatzyl for adult relapsed or refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL). The company has surpassed its initial goal, with 33 U.S. treatment centers now authorized to administer Aucatzyl, potentially covering approximately 60% of the U.S. patient population. This achievement exceeds the company’s target of having 30 centers authorized by the end of the first quarter of 2025. While InvestingPro analysis shows the company holds more cash than debt and maintains strong liquidity with a current ratio of 13.69, it’s worth noting the company is quickly burning through its cash reserves.
Autolus is also anticipating key developments in the second half of 2025. Approval decisions for Aucatzyl in the UK and Europe are expected, along with initial pediatric data. Additionally, the company is looking forward to sharing initial data on systemic lupus erythematosus (SLE) and other autoimmune diseases from its Phase 1 CARLYSLE trial at a research and development event scheduled for April 23, 2025. This data could provide insights into the initial efficacy and quality of the product, with more comprehensive follow-up results anticipated to be presented at a potential conference in the latter half of the year.
The company’s pipeline developments remain a point of interest, particularly after BioNTech (NASDAQ:BNTX) chose not to exercise its option for AUTO1/22 in pediatric B-ALL. However, BioNTech retains an active option for AUTO6NG in solid tumors. Updates on AUTO8 and AUTO6NG are also expected to be shared at the April R&D event, offering a closer look at the progress of these therapies.
Autolus Therapeutics’ efforts in expanding treatment options for serious conditions continue to draw attention from analysts and investors alike, as the company advances its pipeline and expands the availability of its innovative therapies. The stock has experienced significant volatility, trading near its 52-week low of $1.68, with a 70% decline over the past year. Based on InvestingPro’s Fair Value analysis, the stock appears undervalued at current levels.
In other recent news, Autolus Therapeutics reported a net loss of $220.7 million for the fourth quarter of 2024, which is an increase from the $208.4 million loss in the previous year. Despite the increased losses, Autolus saw a significant boost in its cash reserves, reaching $588 million by the end of 2024, primarily due to a $600 million collaboration with BioNTech and equity financing. Truist Securities reaffirmed its Buy rating for Autolus, maintaining a price target of $11, noting the strong demand for Autolus’s Aucatzyl, which surpassed initial site activation goals. The company has activated 33 centers for Aucatzyl, exceeding the target of 30 by the end of the first quarter of 2025. Autolus aims to expand its market presence by targeting 60 centers by the end of the year. Additionally, Ocassol received FDA approval without requiring a REMS program, a significant regulatory milestone for the company. Looking ahead, Truist Securities anticipates that the upcoming New Technology Add-on Payment (NTAP) decision in the fourth quarter could provide financial incentives for centers to choose Aucatzyl over competing therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.